OraSure Technologies (NASDAQ:OSUR) Issues Quarterly Earnings Results

OraSure Technologies (NASDAQ:OSUR - Get Free Report) posted its earnings results on Tuesday. The medical instruments supplier reported ($0.10) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.05) by ($0.05), Zacks reports. OraSure Technologies had a return on equity of 3.55% and a net margin of 5.07%. The business had revenue of $0.04 million for the quarter, compared to the consensus estimate of $36.76 million. OraSure Technologies updated its Q1 2025 guidance to EPS.

OraSure Technologies Price Performance

Shares of OSUR traded up $0.35 during mid-day trading on Friday, hitting $3.48. 1,598,836 shares of the company's stock were exchanged, compared to its average volume of 954,192. The company has a market cap of $259.59 million, a PE ratio of 23.20 and a beta of 0.05. OraSure Technologies has a 52 week low of $2.68 and a 52 week high of $7.81. The company has a 50-day simple moving average of $3.78 and a 200 day simple moving average of $4.00.

Analysts Set New Price Targets

Separately, StockNews.com cut shares of OraSure Technologies from a "buy" rating to a "hold" rating in a research note on Saturday, February 22nd.

Remove Ads

Insider Transactions at OraSure Technologies

In other news, CFO Kenneth J. Mcgrath bought 64,000 shares of the firm's stock in a transaction that occurred on Thursday, February 27th. The stock was acquired at an average cost of $3.15 per share, with a total value of $201,600.00. Following the completion of the purchase, the chief financial officer now owns 371,013 shares of the company's stock, valued at $1,168,690.95. This represents a 20.85 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director John P. Kenny bought 47,659 shares of the firm's stock in a transaction that occurred on Thursday, February 27th. The stock was purchased at an average cost of $3.17 per share, with a total value of $151,079.03. Following the completion of the purchase, the director now directly owns 70,915 shares of the company's stock, valued at $224,800.55. This represents a 204.93 % increase in their position. The disclosure for this purchase can be found here. Insiders acquired 190,284 shares of company stock valued at $600,348 in the last ninety days. 3.40% of the stock is currently owned by corporate insiders.

OraSure Technologies Company Profile

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.